Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • HNRNPU K181 Lactylation Rewires Serine Metabolism

    2026-09-04

    HNRNPU K181 Lactylation Rewires Serine Metabolism

    The reference study, published in Advanced Science, investigates how lactate accumulation is converted into a post-transcriptional signal that supports cervical cancer growth. Its central contribution is the identification of HNRNPU K181 lactylation as a regulatory switch linking tumor-associated lactate to PHGDH expression, serine biosynthesis, and malignant proliferation. The study is available through the journal record for the reference article.

    Study Background and Research Question

    Cervical cancer is characterized not only by genetic and transcriptional alterations but also by metabolic remodeling. Rapidly growing tumor cells commonly accumulate lactate as a consequence of high glycolytic flux. Beyond serving as a metabolic end product, lactate can influence signaling and protein modification, including lysine lactylation. However, the functional importance of lactylation on non-histone proteins in cervical cancer has remained less clearly defined than its role in chromatin regulation.

    The authors focused on HNRNPU, a heterogeneous nuclear ribonucleoprotein associated with RNA processing and post-transcriptional control. Their research question was whether HNRNPU contributes to cervical cancer progression through a regulatory mechanism that is not apparent from its steady-state messenger RNA abundance. This question was motivated by the observation that major HNRNP family members did not show strong tumor-versus-normal differences at the transcript level in the TCGA-CESC analysis, suggesting that protein-level or post-translational regulation could be important.

    The study therefore tested a connected model: lactate-associated lactylation modifies HNRNPU at lysine 181; the modified protein becomes more stable and more effective at regulating PHGDH messenger RNA; and increased PHGDH activity redirects metabolism toward serine production, supporting biosynthetic and redox requirements of cancer cells.

    Key Innovation from the Reference Study

    The principal innovation is the assignment of a specific non-histone lactylation site, HNRNPU K181, to a defined metabolic and oncogenic pathway. Rather than treating lactylation as a broad correlation with glycolytic activity, the study presents K181 as a functionally consequential modification. According to the reference study, K181 lactylation stabilizes HNRNPU and enhances its binding to PHGDH mRNA.

    The work further proposes that HNRNPU regulates the exon 1-containing PHGDH transcript and helps maintain PHGDH mRNA stability. This is important because PHGDH catalyzes the first committed step of the serine biosynthesis pathway. Increased PHGDH expression can therefore increase flux through serine production, supplying metabolites for nucleotide synthesis and helping maintain redox balance during proliferation.

    A second conceptual advance is the proposed competition between lactylation and NAA50-mediated acetylation at the same K181 residue. This model describes K181 as a dynamic post-translational modification switch: lactylation favors HNRNPU stability and PHGDH-linked activity, whereas acetylation may provide an opposing regulatory state. The finding expands the significance of lactate signaling from chromatin-associated regulation to a site-specific control point in RNA-binding protein function.

    Methods and Experimental Design Insights

    The study uses a progression from clinical-data analysis to molecular mechanism and then to tumor-relevant functional testing. This layered design is appropriate for distinguishing expression associations from causal regulatory effects.

    • Expression prioritization: The authors first examined known splicing-factor families using GEPIA and compared transcriptomic patterns in the TCGA-CESC cohort. HNRNPU and related HNRNP proteins were prioritized despite the absence of a strong corresponding tumor-normal mRNA difference.
    • Proteomic context: Protein-level evidence was assessed using the PRIDE dataset PXD055203, which included 136 cervical cancer tissues and 33 normal tissues, as reported in the reference article. This comparison helped address the possibility that post-transcriptional regulation or protein modification, rather than transcript abundance, explains HNRNPU activity.
    • Mechanistic interrogation: The authors examined HNRNPU lactylation at K181, protein stability, interaction with PHGDH mRNA, the exon 1-containing PHGDH transcript, and PHGDH expression. These readouts connect the modification site to RNA regulation rather than stopping at a protein-modification association.
    • Functional validation: Cell-based and in vivo experiments were used to test effects on cervical cancer proliferation, serine metabolism, redox homeostasis, nucleotide synthesis, and tumor growth. The combination of cellular phenotypes with an animal model strengthens the proposed relationship between the molecular axis and disease behavior.
    • Pharmacological assessment: Pazopanib was used to interfere with the HNRNPU K181 lactylation axis. The resulting reduction in PHGDH expression and tumor growth provides translational support, although pharmacological effects require interpretation alongside genetic and biochemical evidence.

    Protocol Parameters

    • Evidence anchor: The reported workflow begins with cervical cancer expression and proteomic prioritization, followed by site-specific HNRNPU lactylation and PHGDH-centered mechanistic assays. These are study parameters, not universal conditions for every model.
    • Dataset scope: The reference study analyzes TCGA-CESC transcriptomic information and PRIDE PXD055203 proteomic data; the reported PRIDE comparison comprises 136 tumor and 33 normal tissues.
    • Mechanistic readouts: A comparable design should measure HNRNPU abundance and stability, K181 modification status, PHGDH mRNA binding, the exon 1-containing transcript, PHGDH expression, and downstream serine-pathway phenotypes.
    • Intervention interpretation: Pazopanib-associated suppression of the axis should be evaluated as a pharmacological observation from this study. Genetic site substitution, modification-specific detection, and rescue experiments would help determine whether the phenotype is attributable specifically to K181 lactylation.

    Core Findings and Why They Matter

    The first major finding is that HNRNPU promotes cervical cancer cell growth even though its regulation is not adequately explained by a simple increase in HNRNPU messenger RNA. This supports a broader view of RNA-binding proteins in cancer: their effects may depend on protein stability, modification state, and interactions with selected transcripts.

    Second, K181 lactylation increases HNRNPU stability and strengthens its association with PHGDH mRNA. Through preservation of the exon 1-containing PHGDH transcript and enhanced mRNA stability, the modified HNRNPU maintains PHGDH expression. This provides a mechanistic explanation for how a lactate-rich tumor environment can reinforce serine biosynthesis without requiring a primary increase in PHGDH gene transcription alone.

    Third, the resulting metabolic rewiring has several consequences. Serine production supports nucleotide synthesis, while pathway activity also contributes to redox homeostasis. These functions are especially relevant to proliferating tumor cells, which must coordinate biomass accumulation with protection from metabolic stress. The study reports that disruption of the HNRNPU-centered axis reduces cervical cancer growth in vitro and in vivo, connecting the biochemical mechanism to a measurable tumor phenotype.

    Finally, the competitive relationship between K181 lactylation and NAA50-mediated acetylation suggests that HNRNPU activity may be responsive to the relative abundance of metabolic and enzymatic inputs. This is more informative than a static modification model because it frames HNRNPU as an integration point between lactate availability, post-translational modification, RNA handling, and metabolic flux. Pazopanib-mediated suppression of HNRNPU K181 lactylation, PHGDH expression, and tumor growth further indicates that this axis may be pharmacologically tractable, although selectivity remains an important question.

    Comparison with Existing Internal Articles

    The internal article HNRNPU K181 Lactylation Rewires Serine Metabolism presents a concise interpretation of the same study and emphasizes the lactate-responsive nature of the modification. It is useful as a conceptual summary, whereas the reference paper provides the primary evidence for the K181, PHGDH, and tumor-growth relationships.

    A second related resource, HNRNPU K181 Lactylation Rewires Serine Metabolism in Cervical Cancer, similarly highlights the proposed molecular switch and its metabolic consequences. Both internal articles are best treated as navigation and interpretation aids rather than independent confirmation. The distinctive contribution of the reference study is the integration of site-specific modification, RNA regulation, serine metabolism, and in vivo tumor biology.

    Limitations and Transferability

    Several limitations should guide interpretation. Database-based prioritization can identify biologically plausible candidates but cannot establish that HNRNPU is regulated by lactylation in every cervical cancer subtype. Tissue proteomic comparisons also provide context rather than direct evidence that K181 modification is the cause of increased PHGDH activity. The causal model therefore depends on the specificity and reproducibility of the site-directed molecular experiments.

    The proposed modification switch also requires careful biochemical validation. Because lactylation and acetylation occupy the same lysine, changes in one signal may alter the other indirectly through substrate competition, enzyme activity, or cellular metabolic state. Likewise, Pazopanib is a pharmacological intervention and its suppression of tumor growth should not by itself be interpreted as proof of selective action on HNRNPU K181 lactylation. Orthogonal genetic perturbation and rescue designs are important for separating pathway-specific effects from broader drug responses.

    Transferability beyond cervical cancer remains an open question. The HNRNPU-PHGDH relationship may be relevant in other lactate-rich malignancies, but tissue lineage, oncogenic background, nutrient availability, and serine dependence could change the strength or direction of the effect. Future work should therefore test the axis across independent models while retaining the same site-specific, RNA-centered, and metabolic readouts. The most defensible outlook is that HNRNPU K181 lactylation represents a promising mechanistic vulnerability, not yet a universally validated cancer pathway.

    Research Support Resources

    Researchers extending this work into ubiquitin-proteasome system research may use (R)-MG132 (SKU C3348) as a functionally inactive MG-132 enantiomer and negative control when proteasome perturbation is added to a cell-based assay. Its reported minimal inhibition of the 20S proteasome chymotrypsin-like activity makes it relevant to proteasome inhibition validation and cell-based assay proteasome control, helping distinguish proteasome-dependent effects from nonspecific cellular responses. It was not part of the reference study; any use in mechanistic studies of proteasome-linked metabolism should include matched active-compound, vehicle, and assay-specific controls. The product information recommends storage at -20 °C and prompt use of prepared solutions.